The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Drugs for Non-Small Cell Lung Cancer-Global Market Insights and Sales Trends 2024
Synopsis
The global Drugs for Non-Small Cell Lung Cancer market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Drugs for Non-Small Cell Lung Cancer in various end use industries. The expanding demands from the Hospitals, Clinics and Other, are propelling Drugs for Non-Small Cell Lung Cancer market. Radiofrequency Ablation (RFA), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Radiation Therapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Drugs for Non-Small Cell Lung Cancer, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Drugs for Non-Small Cell Lung Cancer market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Drugs for Non-Small Cell Lung Cancer market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Drugs for Non-Small Cell Lung Cancer sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Drugs for Non-Small Cell Lung Cancer covered in this report include Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Sanofi, Ziopharm Oncology, Alchemia, Amgen, Apotex and BioMarin Pharmaceutical, etc.
The global Drugs for Non-Small Cell Lung Cancer market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
Global Drugs for Non-Small Cell Lung Cancer market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Drugs for Non-Small Cell Lung Cancer market, Segment by Type:
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Global Drugs for Non-Small Cell Lung Cancer market, by Application
Hospitals
Clinics
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Drugs for Non-Small Cell Lung Cancer companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Drugs for Non-Small Cell Lung Cancer market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Drugs for Non-Small Cell Lung Cancer in various end use industries. The expanding demands from the Hospitals, Clinics and Other, are propelling Drugs for Non-Small Cell Lung Cancer market. Radiofrequency Ablation (RFA), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Radiation Therapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Drugs for Non-Small Cell Lung Cancer, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Drugs for Non-Small Cell Lung Cancer market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Drugs for Non-Small Cell Lung Cancer market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Drugs for Non-Small Cell Lung Cancer sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Drugs for Non-Small Cell Lung Cancer covered in this report include Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Sanofi, Ziopharm Oncology, Alchemia, Amgen, Apotex and BioMarin Pharmaceutical, etc.
The global Drugs for Non-Small Cell Lung Cancer market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
Global Drugs for Non-Small Cell Lung Cancer market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Drugs for Non-Small Cell Lung Cancer market, Segment by Type:
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Global Drugs for Non-Small Cell Lung Cancer market, by Application
Hospitals
Clinics
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Drugs for Non-Small Cell Lung Cancer companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Drugs for Non-Small Cell Lung Cancer
1.1 Drugs for Non-Small Cell Lung Cancer Market Overview
1.1.1 Drugs for Non-Small Cell Lung Cancer Product Scope
1.1.2 Drugs for Non-Small Cell Lung Cancer Market Status and Outlook
1.2 Global Drugs for Non-Small Cell Lung Cancer Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Drugs for Non-Small Cell Lung Cancer Market Size by Region (2018-2029)
1.4 Global Drugs for Non-Small Cell Lung Cancer Historic Market Size by Region (2018-2023)
1.5 Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Drugs for Non-Small Cell Lung Cancer Market Size (2018-2029)
1.6.1 North America Drugs for Non-Small Cell Lung Cancer Market Size (2018-2029)
1.6.2 Europe Drugs for Non-Small Cell Lung Cancer Market Size (2018-2029)
1.6.3 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size (2018-2029)
1.6.4 Latin America Drugs for Non-Small Cell Lung Cancer Market Size (2018-2029)
1.6.5 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size (2018-2029)
2 Drugs for Non-Small Cell Lung Cancer Market by Type
2.1 Introduction
2.1.1 Radiofrequency Ablation (RFA)
2.1.2 Radiation Therapy
2.1.3 Chemotherapy
2.1.4 Targeted Therapies
2.1.5 Immunotherapy
2.2 Global Drugs for Non-Small Cell Lung Cancer Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Drugs for Non-Small Cell Lung Cancer Historic Market Size by Type (2018-2023)
2.2.2 Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Drugs for Non-Small Cell Lung Cancer Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Drugs for Non-Small Cell Lung Cancer Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Drugs for Non-Small Cell Lung Cancer Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Drugs for Non-Small Cell Lung Cancer Revenue Breakdown by Type (2018-2029)
3 Drugs for Non-Small Cell Lung Cancer Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Other
3.2 Global Drugs for Non-Small Cell Lung Cancer Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Drugs for Non-Small Cell Lung Cancer Historic Market Size by Application (2018-2023)
3.2.2 Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Drugs for Non-Small Cell Lung Cancer Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Drugs for Non-Small Cell Lung Cancer Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Drugs for Non-Small Cell Lung Cancer Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Drugs for Non-Small Cell Lung Cancer Revenue Breakdown by Application (2018-2029)
4 Drugs for Non-Small Cell Lung Cancer Competition Analysis by Players
4.1 Global Drugs for Non-Small Cell Lung Cancer Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Drugs for Non-Small Cell Lung Cancer as of 2022)
4.3 Date of Key Players Enter into Drugs for Non-Small Cell Lung Cancer Market
4.4 Global Top Players Drugs for Non-Small Cell Lung Cancer Headquarters and Area Served
4.5 Key Players Drugs for Non-Small Cell Lung Cancer Product Solution and Service
4.6 Competitive Status
4.6.1 Drugs for Non-Small Cell Lung Cancer Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Bristol-Myers Squibb
5.1.1 Bristol-Myers Squibb Profile
5.1.2 Bristol-Myers Squibb Main Business
5.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.1.4 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.1.5 Bristol-Myers Squibb Recent Developments
5.2 GlaxoSmithKline
5.2.1 GlaxoSmithKline Profile
5.2.2 GlaxoSmithKline Main Business
5.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.2.4 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.2.5 GlaxoSmithKline Recent Developments
5.3 Menarini
5.3.1 Menarini Profile
5.3.2 Menarini Main Business
5.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.3.4 Menarini Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.3.5 Sanofi Recent Developments
5.4 Sanofi
5.4.1 Sanofi Profile
5.4.2 Sanofi Main Business
5.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.4.4 Sanofi Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.4.5 Sanofi Recent Developments
5.5 Ziopharm Oncology
5.5.1 Ziopharm Oncology Profile
5.5.2 Ziopharm Oncology Main Business
5.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.5.4 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.5.5 Ziopharm Oncology Recent Developments
5.6 Alchemia
5.6.1 Alchemia Profile
5.6.2 Alchemia Main Business
5.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.6.4 Alchemia Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.6.5 Alchemia Recent Developments
5.7 Amgen
5.7.1 Amgen Profile
5.7.2 Amgen Main Business
5.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.7.4 Amgen Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.7.5 Amgen Recent Developments
5.8 Apotex
5.8.1 Apotex Profile
5.8.2 Apotex Main Business
5.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.8.4 Apotex Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.8.5 Apotex Recent Developments
5.9 BioMarin Pharmaceutical
5.9.1 BioMarin Pharmaceutical Profile
5.9.2 BioMarin Pharmaceutical Main Business
5.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.9.4 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.9.5 BioMarin Pharmaceutical Recent Developments
5.10 CellAct Pharma
5.10.1 CellAct Pharma Profile
5.10.2 CellAct Pharma Main Business
5.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.10.4 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.10.5 CellAct Pharma Recent Developments
5.11 Cerulean Pharma
5.11.1 Cerulean Pharma Profile
5.11.2 Cerulean Pharma Main Business
5.11.3 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.11.4 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.11.5 Cerulean Pharma Recent Developments
5.12 Cipla
5.12.1 Cipla Profile
5.12.2 Cipla Main Business
5.12.3 Cipla Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.12.4 Cipla Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.12.5 Cipla Recent Developments
5.13 Cornerstone Pharmaceuticals
5.13.1 Cornerstone Pharmaceuticals Profile
5.13.2 Cornerstone Pharmaceuticals Main Business
5.13.3 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.13.4 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.13.5 Cornerstone Pharmaceuticals Recent Developments
5.14 Curis
5.14.1 Curis Profile
5.14.2 Curis Main Business
5.14.3 Curis Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.14.4 Curis Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.14.5 Curis Recent Developments
5.15 CytRx
5.15.1 CytRx Profile
5.15.2 CytRx Main Business
5.15.3 CytRx Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.15.4 CytRx Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.15.5 CytRx Recent Developments
5.16 Eli Lilly
5.16.1 Eli Lilly Profile
5.16.2 Eli Lilly Main Business
5.16.3 Eli Lilly Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.16.4 Eli Lilly Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.16.5 Eli Lilly Recent Developments
5.17 Exelixis
5.17.1 Exelixis Profile
5.17.2 Exelixis Main Business
5.17.3 Exelixis Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.17.4 Exelixis Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.17.5 Exelixis Recent Developments
5.18 Fresenius Kabi
5.18.1 Fresenius Kabi Profile
5.18.2 Fresenius Kabi Main Business
5.18.3 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.18.4 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.18.5 Fresenius Kabi Recent Developments
5.19 Genentech
5.19.1 Genentech Profile
5.19.2 Genentech Main Business
5.19.3 Genentech Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.19.4 Genentech Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.19.5 Genentech Recent Developments
5.20 Hikma Pharmaceuticals
5.20.1 Hikma Pharmaceuticals Profile
5.20.2 Hikma Pharmaceuticals Main Business
5.20.3 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.20.4 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.20.5 Hikma Pharmaceuticals Recent Developments
5.21 Hospira
5.21.1 Hospira Profile
5.21.2 Hospira Main Business
5.21.3 Hospira Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.21.4 Hospira Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.21.5 Hospira Recent Developments
5.22 Intas Pharmaceuticals
5.22.1 Intas Pharmaceuticals Profile
5.22.2 Intas Pharmaceuticals Main Business
5.22.3 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.22.4 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.22.5 Intas Pharmaceuticals Recent Developments
5.23 Karyopharm Therapeutics
5.23.1 Karyopharm Therapeutics Profile
5.23.2 Karyopharm Therapeutics Main Business
5.23.3 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.23.4 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.23.5 Karyopharm Therapeutics Recent Developments
5.24 Kyowa Hakko Kirin
5.24.1 Kyowa Hakko Kirin Profile
5.24.2 Kyowa Hakko Kirin Main Business
5.24.3 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.24.4 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.24.5 Kyowa Hakko Kirin Recent Developments
5.25 Ligand Pharmaceuticals
5.25.1 Ligand Pharmaceuticals Profile
5.25.2 Ligand Pharmaceuticals Main Business
5.25.3 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
5.25.4 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue (US$ Million) & (2018-2023)
5.25.5 Ligand Pharmaceuticals Recent Developments
6 North America
6.1 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Drugs for Non-Small Cell Lung Cancer Market Dynamics
11.1 Drugs for Non-Small Cell Lung Cancer Industry Trends
11.2 Drugs for Non-Small Cell Lung Cancer Market Drivers
11.3 Drugs for Non-Small Cell Lung Cancer Market Challenges
11.4 Drugs for Non-Small Cell Lung Cancer Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
